1. |
Menon B, Shorvon SD. Ischaemic stroke in adults and epilepsy. EpilepsyRes, 2009, 87(2):1-11.
|
2. |
Hesdorffer DC, Benn EKT, Cascino GD, et al. Is a first acute symptomaticseizure epilepsy Mortality and risk for recurrent seizure.Epilepsia, 2009, 50(11):1102-1108.
|
3. |
Fisher RS, Acevedo C, Arzimanoglou A, et al. A practical clinical definitionof epilepsy. Epilepsia, 2014, 55(8):475-482.
|
4. |
Gasparini S, Ferlazzo E, Beghi E, et al. Epilepsy associated withLeukoaraiosis mainly affects temporal lobe: a casual or causal relationship. Epilepsy Res, 2015, 109(2):1-8.
|
5. |
Pantoni L. Cerebral small vessel disease: from pathogenesis and clinicalcharacteristics to therapetic challenges. Lancet Neurol, 2010, 9(2): 689-701.
|
6. |
Guidelines for epidemiologic studies on epilepsy. Commission on Epidemiologyand Prognosis, International League Against Epilepsy.Epilepsia, 1993, 34(5):592-596.
|
7. |
Cuomo O, Rispoli V, Leo A, et al. The antiepileptic drug levetiracetamsuppresses non-convulsive seizure activity and reduces ischemic braindamage in rats subjected to permanent middle cerebral artery occlusion.PLoS ONE, 2013, 8(6):e80852.
|
8. |
Watson BD, Dietrich WD, Busto R, et al. Induction of reproduciblebrain infarction by photochemically initiated thrombosis. Ann Neurol, 1985, 17(5):497-504.
|
9. |
Karhunen H, Bezvenyuk Z, Nissinen J, et al. Epileptogenesis after corticalphotothrombotic brain lesion in rats. Neuroscience 2007, 48(10):314-324.
|
10. |
Kessler KR, Schnitzler A, Classen J, et al. Reduced inhibition withinprimary motor cortex in patients with posts-troke focal motor seizures.Neurology, 2002, 59(7):1028-1033.
|
11. |
Kim JH, Lee HW, Cohen LG, et al. Motor cortical excitability inpatients with post-stroke epilepsy. Epilepsia, 2008, 49(10):117-124.
|
12. |
Kaiser D, Weise G, Meoller K, et al. Spontaneous white matter damage, cognitive decline and neuro-inflammation in middle-aged hypertensiverats: an animal model of early-stage cerebral small vessel disease. ActaNeuropatholCommun, 2014, 2(3):169.
|
13. |
Tchekalarova J, Georgiev V. Angiotensin peptides modulatory system:how is it implicated n the control of seizure susceptibility. Life Sci, 2005, 76(9):955-970.
|
14. |
Tchekalarova J, Loyens E, Smolders I. Effects of AT1 receptor antagonismon kainate-induced seizures and concomitant changes in hippocampalextracellular noradrenaline, serotonin, and dopamine levelsin Wistar-Kyoto and spontaneously hypertensive rats. Epilepsy Behav, 2015, 46(8):66-71.
|
15. |
Arganaraz GA, Konno AC, Perosa SR, et al. The renin-angiotensinsystem is up-regulated in the cortex and hippocampus of patients withtemporal lobe epilepsy related to mesial temporal sclerosis. Epilepsia, 2008, 49(11):1348-1357.
|
16. |
Ng SK, Hauser WA, Brust JC, et al. Hypertension and the risk of newonsetunprovoked seizures. Neurology, 1993, 43(2):425-428.
|
17. |
Hesdorffer DC, Hauser WA, Annegers JF, et al. Severe, uncontrolledhypertension and adult-onset seizures: a case-control study in Rochester, Minnesota. Epilepsia, 1996, 37(2):736-741.
|
18. |
Li X, Breteler MM, deBruyne MC, et al. Vascular determinants of epilepsy:the Rotterdam Study. Epilepsia, 1997, 38(4):216-220.
|
19. |
Maxwell H, Hanby M, Parkes LM, et al. Prevalence andsubtypes of radiological cerebrovascular disease in late-onset isolatedseizures and epilepsy. ClinNeurolNeurosurg, 2013, 115(10):591-596.
|
20. |
Okroglic S, Widmann CN, Urbach H, et al. Clinical symptoms and riskfactors in cerebral microangiopathy patients. PloS ONE, 2013, 8(4):e53455.
|
21. |
De Reuck J, Van Maele G. Cognitive impairment and seizures inpatients with lacunar strokes. EurNeurol, 2009, 61(4):159-163.
|
22. |
Smith EE, Schneider JA, Wardlaw JM, et al. Cerebral microinfarcts:the invisible lesions. Lancet Neurol, 2012, 11(7):272-282.
|
23. |
Keller L, Hobohm C, Zeynalova S, et al. Does treatment with t-PAincrease the risk of developing epilepsy after stroke. J Neurol, 2015, 262(4):2364-2372.
|
24. |
Serafini A, Gigli GL, Gregoraci G, et al. Are early seizures predictiveof epilepsy after a stroke Results of a population-based study Neuroepidemiology, 2015, 45(4):50-58.
|
25. |
Zhang C, Wang X, Wang Y, et al. Risk factors for post-strokeseizures:a systematic review and meta-analysis. Epilepsy Res, 2014, 108(7):1806-1816.
|
26. |
De Reuck J, Nagy E, Van Maele G. Seizures and epilepsy in patientswith lacunar strokes. J NeurolSci, 2007, 263(10):75-78.
|
27. |
Ferlazzo E, Sueri C, Gasparini S, et al. Challenges in the pharmacologicalmanagement of epilepsy and its causes in the elderly. PharmacolRes, 2016, 106(4):21-26.
|
28. |
Semah F, Picot MC, Adam C, et al. Is the underlying cause of epilepsya major prognostic factor for recurrence Neurology, 1998, 51(4):1256-1262.
|
29. |
Stephen LJ, Kwan P, Brodie MJ. Does the cause of localisation-relatedepilepsy influence the response to antiepileptic drug treatment.Epilepsia, 2001, 42(7):357-362.
|
30. |
Gilad R, Boaz M, Dabby R, et al. Are post intracerebral hemorrhageseizures prevented by antiepileptic treatment. Epilepsy Res, 2011, 95(6):227-231.
|
31. |
Gilad R, Sadeh M, Rapoport A, et al. Monotherapy of lamotrigine versuscarbamazepine in patients with poststroke seizure. ClinNeuropharmacol, 2007, 30(5):189-195.
|
32. |
Kutlu G, Gomceli YB, Unal Y, et al. Levetiracetam monotherapy forlate post-stroke seizures in the elderly. Epilepsy Behav, 2008, 13(4):542-544.
|
33. |
Belcastro V, Costa C, Galletti F, et al. Levetiracetam in newly diagnosedlate-onset post-stroke seizures: a prospective observationalstudy. Epilepsy Res, 2008, 82(1):223-226.
|
34. |
Consoli D, Bosco D, Postorino P, et al. Levetiracetam versus carbamazepinein patients with late poststroke seizures: a multicenterprospective randomized open-label study (EpIC Project). CerebrovascDis, 2012, 34(8):282-289.
|
35. |
Huang YH, Chi NF, Kuan YC, et al. Efficacy of phenytoin, valproicacid, carbamazepine and new antiepileptic drugs on control of lateonsetpost-stroke epilepsy in Taiwan. Eur J Neurol, 2015, 22(7):1459-1468.
|
36. |
Brodie MJ, Overstall PW, Giorgi L. Multicenter, double-blind, randomizedcomparison between lamotrigine and carbamazepine inelderly patients with newly diagnosed epilepsy. Epilepsy Res, 1999, 37(2):81-87.
|
37. |
Rowan AJ, Ramsay RE, Collins JF, et al. New onset geriatric epilepsy:a randomized study of gabapentin, lamotrigine, and carbamazepine.Neurology, 2005, 64(6):1868-1873.
|
38. |
Marson AG, Al-Kharusi AM, Alwaidh M, et al. SANAD study ofeffectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblendedrandomized controlled trial. Lancet, 2007, 369(11):1000-1015.
|
39. |
Saetre E, Perucca E, Isojarvi J, et al. An international multicenter randomizeddouble-blind controlled trial of lamotrigine and sustainedreleasecarbamazepine in the treatment of newly diagnosed epilepsy inthe elderly. Epilepsia, 2007, 48(2):1292-1302.
|
40. |
Werhahn KJ, Trinka E, Dobesberger J, et al. A randomized, doubleblindcomparison of antiepileptic drug treatment in the elderly withnew-onset focal epilepsy. Epilepsia, 2015, 56(5):450-459.
|